The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Biomarker; Pharmacodynamics
- Acronyms WELCOME
- 17 Apr 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 17 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 31 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.